OS Therapies
OS Therapies is a clinical-stage cancer immunotherapy company dedicated to developing innovative treatments for Osteosarcoma and other solid tumors. Their mission is to revolutionize cancer treatment by leveraging HER2 targeted therapies and novel immunotherapy platforms, aiming to address unmet medical needs and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
OS Therapies
101 6th Avenue, 3rd Floor, JnJ JLABS NYC, New York, NY 10013
Products
Listeria-based HER2-targeted immunotherapy (vaccine)
An immunotherapy platform that uses an attenuated bacterial vector to present HER2 antigen, activate antigen-presenting cells and induce HER2-specific T cell responses aimed at preventing recurrence and targeting micro-metastases.
Tunable antibody-drug conjugate platform with pH-cleavable linker and conditionally active payloads
A tunable ADC platform using small targeting ligands for deeper tumor penetration, a silicon-based pH-cleavable linker to release payloads in endosomes/acidic tumor microenvironments, and conditionally active payloads that selectively permeate and kill cancer cells under acidic conditions.
Listeria-based HER2-targeted immunotherapy (vaccine)
An immunotherapy platform that uses an attenuated bacterial vector to present HER2 antigen, activate antigen-presenting cells and induce HER2-specific T cell responses aimed at preventing recurrence and targeting micro-metastases.
Tunable antibody-drug conjugate platform with pH-cleavable linker and conditionally active payloads
A tunable ADC platform using small targeting ligands for deeper tumor penetration, a silicon-based pH-cleavable linker to release payloads in endosomes/acidic tumor microenvironments, and conditionally active payloads that selectively permeate and kill cancer cells under acidic conditions.
Services
Multi-site clinical trial evaluating a HER2-directed immunotherapy in patients with resected, recurrent osteosarcoma; includes safety assessment and preliminary efficacy endpoints with enrollment completed across pediatric oncology sites.
Chemical assembly, control of payload stoichiometry, and purification processes for tunable antibody-drug conjugates intended for targeted therapeutic use.
Preclinical evaluation including translational efficacy studies (canine models) and toxicology studies to characterize safety of tunable drug conjugates and immunotherapies.
Multi-site clinical trial evaluating a HER2-directed immunotherapy in patients with resected, recurrent osteosarcoma; includes safety assessment and preliminary efficacy endpoints with enrollment completed across pediatric oncology sites.
Chemical assembly, control of payload stoichiometry, and purification processes for tunable antibody-drug conjugates intended for targeted therapeutic use.
Preclinical evaluation including translational efficacy studies (canine models) and toxicology studies to characterize safety of tunable drug conjugates and immunotherapies.
Expertise Areas
- Immunotherapy development (HER2-directed)
- Antibody-drug conjugate (ADC) design and CMC
- Clinical trial management in pediatric oncology
- Translational oncology (including canine models)
Key Technologies
- Bacterial-vector vaccine platform
- HER2-targeted immunotherapy
- Tunable antibody-drug conjugates
- pH-cleavable silicon linker chemistry